Intensity Therapeutics (INTS) Total Non-Current Liabilities (2022 - 2024)
Intensity Therapeutics' (INTS) quarterly Total Non-Current Liabilities came in at $1.9 million in Q4 2024, down 54.48% YoY from $4.1 million in Q1 2024, and down 23.38% on a QoQ basis from $2.4 million in Q3 2024.
Intensity Therapeutics (INTS) Total Non-Current Liabilities (2022 - 2024) Analysis & Trends
Intensity Therapeutics (INTS) has 3 years of Total Non-Current Liabilities data on file, last reported at $1.9 million in Q4 2024.
- Quarterly Total Non-Current Liabilities fell 54.48% year-over-year to $1.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.9 million (down 54.48% YoY) and the FY2024 annual result came in at $1.9 million, down 54.48% from the prior year.
- Total Non-Current Liabilities retreated to $1.9 million in Q4 2024, from $2.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $6.8 million in Q4 2022 to a low of $868857.0 in Q3 2023.
- A 3-year average of $3.2 million and a median of $2.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 180.14% in 2024, down 54.48% in 2024.
- Tracing INTS's Total Non-Current Liabilities over 3 years: stood at $6.8 million in 2022, then slumped by 39.92% to $4.1 million in 2023, then tumbled by 54.48% to $1.9 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $1.9 million (Q4 2024), $2.4 million (Q3 2024), and $3.3 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.87 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 4.10 Mn |
| Sep 30, 2023 | 868,857.00 |
| Dec 31, 2022 | 6.82 Mn |